Oryzon Genomics S.A.
MCE ORY.MC
Oryzon Genomics S.A. Revenue for the year ending December 31, 2023: USD 15.66 M
-
Oryzon Genomics S.A. Revenue for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
-
Oryzon Genomics S.A. Revenue for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
-
Oryzon Genomics S.A. Revenue for the year ending December 31, 2020 was USD 0.00.
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
| CEO | Dr. Carlos Manuel Buesa Arjol |
| IPO Date | Dec. 14, 2015 |
| Location | Spain |
| Headquarters | Sant Ferran 74 |
| Employees | 46 |
| Sector | Health Care |
| Industries | |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email